Clinical trials: Anticoagulant
Blood Donors
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
This study will evaluate a new blood collection and filtration system that is intended to be used to collect, filter, separate and store red blood cells and, separately, plasma.
- Trial name
- NCT02145507
- Testing
- SOLX (Investigational), AS-3 (Control)
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Anticoagulant
A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
This study will be a single-center, randomized, single-dose, open-label, two-treatment, two-period, two-sequence crossover bioequivalence study to compare the rate and extent of absorption of WD-1602 granule formulation (WD…
- Trial name
- NCT04592822
- Testing
- WD-1602, Pradaxa®
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Healthy Male Volunteers
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a…
- Trial name
- NCT07744386
- Testing
- Dabigatran Etexilate, Rosuvastatin, CHF10196
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Anticoagulants, Self Efficacy
Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
This study aims to develop and validate an index measurement tool to assess the patient's self-care self-efficacy in managing oral anticoagulation therapy (OAC).
- Conditions
- Anticoagulants, Self Efficacy, Self Confidence
- Trial name
- SCSE-OAC (NCT05820854)
- Testing
- Self-assess and reporting self-care self-efficacy levels
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03578146
- Testing
- PRT064445/Rivaroxaban
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Thrombosis
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
- Trial name
- NCT01379300
- Testing
- dabigatran etexilate, rivaroxaban
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation (AF), Ischemic Stroke
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
- Trial name
- SAFER-DOAC (NCT07713537)
- Testing
- DOAC Level
- Where
- 2 sites in Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Anticoagulant Drugs, Diabetes Mellitus, Type 2
Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence
In this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.
- Trial name
- NCT03753568
- Testing
- Electronic medicine reminder system
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Atrial Fibrillation, Stroke
A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF
This is a prospective, single-arm, feasibility pilot study of 20 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) recruited from a total of 4 retail and outpatient…
- Trial name
- APOTHECARYAF (NCT04907825)
- Testing
- Oral anticoagulant
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Venous Thromboembolism, Pharmacokinetics
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers.
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Trial name
- ACT (NCT03083782)
- Testing
- Apixaban alone, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
DOAC ADRs Retrospective Study on Genetic Variations
The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e.
- Trial name
- DARES1 (NCT04580589)
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cipherome, Inc.
Thrombosis, Anticoagulant-induced Bleeding
Reversal of the Antithrombotic Action of New Oral Anticoagulants
The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants. 1.
- Conditions
- Thrombosis, Anticoagulant-induced Bleeding, Anticoagulant Overdosage, Hemorrhage
- Trial name
- REVANT (NCT01478282)
- Testing
- Rivaroxaban, Dabigatran
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Gines Escolar
Drug Action Reversal
Reversal of Dabigatran With Prothrombin Complex Concentrate
The purpose of this study is to investigate whether Prothrombin Complex Concentrate (PCC) is effective in reversing the anticoagulant effect of Dabigatran, as assessed by two modified skin-bleeding tests.
- Trial name
- NCT02463591
- Testing
- Beriplex
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Anticoagulant Disorders
Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures
The use of Direct Oral Anti-Coagulants (DOACs) is expanding, but their proper management in patients undergoing endoscopic procedures is still not completely clear. Current European guidelines are based on weak data.
- Trial name
- NCT02734316
- Testing
- endoscopic procedure
- Where
- Italy
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- Valduce Hospital
Hypertriglyceridemia
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
The primary objective of this study is to determine the effect of Epanova® on the pharmacokinetic and anticoagulant activity of warfarin.
- Trial name
- NCT01431690
- Testing
- warfarin, omefas, omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anticoagulants and Bleeding Disorders
Anticoagulation and Antiplatelet Management During Perioperative Period
the investigators hypothesize that patients do not understand these therapies, and that they are poorly undertaken. In some cases, the anesthesiologist does not understand correctly the indication of the treatment due to lack of…
- Trial name
- OMAHA (NCT03871283)
- Where
- Belgium
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Older Adults (65 Years and Older), Falls
Healthcare Services for Older People Who Have Fallen With Potential Head Injury
Every year, one in three older people (>65 years old) experience a fall. Older people may have long-term health conditions and take medications that can increase their risk of bleeding (blood thinners).
- Conditions
- Older Adults (65 Years and Older), Falls, Head Injury
- Trial name
- Anti-HI-Falls (NCT07111871)
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Thrombosis
Vitamin K2 Intervention in Patients With Vitamin K Antagonists
The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy…
- Trial name
- SAFEK (NCT01533441)
- Testing
- Vitamin K2
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Danisco
Healthy
Genetic Response to Warfarin in Healthy Subjects
The purpose of this study is to determine the importance of genetic differences on individuals' response to warfarin in a group of healthy subjects.
- Trial name
- NCT01520402
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai